SECsense Logo

ImmunoPrecise Antibodies Ltd. 6-K Report: January 2025 Insights & Compliance

$IPA
Form 6-K
Filed on: 2025-01-03
Source
ImmunoPrecise Antibodies Ltd. 6-K Report: January 2025 Insights & Compliance

Here are the key insights and information extracted from the provided section of the financial report for ImmunoPrecise Antibodies Ltd.:

  1. Filing Information:
  • Form: 6-K
  • Commission File Number: 001-39530
  • Filing Date: January 3, 2025
  • Reporting Period: For the month of January 2025
  1. Company Details:
  • Name: ImmunoPrecise Antibodies Ltd.
  • Address: 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8
  1. Incorporation by Reference:
  • The report includes an incorporation by reference statement for Exhibit 99.1 into various registration statements:
    • Form F-3: File Nos. 333-273197, 333-281312
    • Form S-8: File No. 333-256730
  1. Exhibit Index:
  • Exhibit 99.1: Material Change Report dated January 2, 2025.
  1. Signature:
  • The report was signed by Jennifer Bath, who is the President and Chief Executive Officer of ImmunoPrecise Antibodies Ltd.
  1. Regulatory Compliance:
  • The filing complies with the requirements of the Securities Exchange Act of 1934.

Summary:

This 6-K filing primarily informs about the company's recent material change report and confirms its compliance with SEC regulations. It emphasizes the company's ongoing commitment to transparency and regulatory adherence. The involvement of the CEO in signing the report indicates the significance of the information disclosed.